Damon Reed, MD
Disclosures: Membership on Advisory Committees or Review Panels, Board Membership, etc.-Eisai Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-pfizer - 10/15/2021
OMB No. 0925-0001/0002 (Rev. 08/12), Biographical Sketch Format Page

OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)


Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.

NAME:  Reed, Damon             


POSITION TITLE:  Pediatric Hematologist/Oncologist

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)



(if applicable)


Completion Date





Case Western Reserve University




Boston Combined Residency in Pediatrics




St. Jude Children’s Research Hospital



Pediatric Hematology/Oncology


A.              Personal Statement                           

As the Director of the Adolescent and Young Adult (AYA) Program I focus on team science across cancer types to better elucidate and address biologic and psychosocial needs of AYA patients towards improving outcomes.  I am proud of the team science we’ve been able to accomplish at Moffitt that spans the unique needs of AYA cancer patients. 


As an evolutionary oncologist, I focus on translating agents, combinations and strategies for pediatric, adolescent and young adult sarcoma patients through clinical trials.  Most importantly, I wish to develop a trial framework that allows more robust measures of perturbation of tumors and anticipates how cancers resist and evolve in response to therapies.  Conceptually I think of evolutionary oncology as precision medicine over time and thus aspire to anticipate tumor adaptation to each systemic therapy I apply.  I am expanding the investigation of ecological and evolutionary inspired treatment approaches through Moffitt’s novel evolutionary tumor board which I clinically co-lead with Dr. Christine Chung.  The opportunity to continue work from basic science through preclinical and trial development with innovative teams such as our institution’s Integrated Mathematical Oncology department and particularly Drs. Bob Gatenby, Joel Brown, Sandy Anderson, Andriy Marusyk, Mark Robertson-Tessi and Bob Gillies along with Dr. Conor Lynch in the Cancer Biology and Evolution Program as the primary area of focus for me moving forward.


As the Vice Chair of the Bone Tumor Committee at the Children’s Oncology Group, I have the opportunity to shape the major phase 2 and 3 trials through the cooperative group and across the NCTN. Investigator initiated trials currently being developed or accruing patients include: an evolutionary inspired protocol for metastatic, fusion positive rhabdomyosarcomas, a Phase 2 study investigating DS-8201a in osteosarcoma through the Children’s Oncology Group and a phase 2 studying Azacitadine and Nivolumab in osteosarcoma through the NPCF’s Sunshine Project, and I am the PI of the first in human Phase I trial of the LSD1 inhibitor Seclidemstat in Ewing sarcoma.  I have also worked with a team creating a trial to assess circulating tumor cells and DNA over time in newly diagnosed sarcoma patients.  As the Leader of the National Pediatric Cancer Foundation’s Sunshine Project, I ensure that this growing multi-institutional network conducts innovative trials safely across over 20 institutions.  These Sunshine Project investigator-initiated trials have enrolled over 80 patients, and two of the trials have been published.  We continue to develop more exciting trials across the network with innovative correlates, promising agents & schedules through nimble hybrid funding models.  In the lab, I am developing and characterizing the phenotype and genotypes of osteosarcoma cell lines and co-culturing these cell lines towards an idealized intratumoral heterogeneity model.


Ongoing and recently completed projects that I would like to highlight include:

National Pediatric Cancer Foundation


07/01/2010 to 06/30/2022

The Sunshine Project




04/22/2020 to 04/30/2024

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma




07/01/2020 to 06/30/2022             

Building the osteosarcoma data commons




03/29/2019 to 03/31/2023

A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma




03/01/2019 to 02/28/2024

COMMITTEE LEADERSHIP: NIH National Clinical Trials Network (NCTN) Grant




09/20/2019 to 07/31/2024

STUDY CHAIR, NIH Pediatric Early Phase Clinical Trial Network (PEP-CTN) Grant (UM1CA228823) Successor to NIH Phase I Grant (2UM1CA097452); COG protocol PEPN1924


Completed within last 3 years

NIH R01CA187532-05


04/06/2015 to 03/31/2020

Imaging Habitats in Sarcoma


B.              Positions, Scientific Appointments, and Honors

2021-present              Senior Member, Moffitt Cancer Center

2014-2021              Associate Member Sarcoma Department, Moffitt Cancer Center, Tenure beginning 2017

2014-present              Associate Professor, Department of Oncologic Sciences and Department of Pediatrics, USF

2010-2013              Assistant Member Sarcoma Department, Moffitt Cancer Center

2008-2010              Courtesy Assistant Member Sarcoma Department, Moffitt Cancer Center

2005-2008              Clinical Postdoctoral Fellow, St. Jude Children’s Research Hospital

2002-2005              Clinical Fellow in Pediatrics, Harvard Medical School

2002-2005              Teaching Fellow in Pediatrics, Boston University School of Medicine



2008-present              ASCO, AACR, CTOS (board member 2017-present, Treasurer 2021), COG (Vice Chair, Bone Committee; Associate Vice Chair, Career Development & Publications, AYA Committee)



2008-present              Florida Medical License. ME101596

2005-2008              Tennessee Medical License

2002-2005              Massachusetts Medical License (limited)


Board Certifications:

2008-present              American Board of Pediatrics: Pediatric Hematology/Oncology Board certified, Exam Date March 30, 2009

2005-2015              American Board of Pediatrics: Pediatric Medical Board certified



Sept 2015              Dick Vitale Heart of Gold Award Recipient: Pediatric Cancer Foundation

July 2015              Finalist (of 3): Critical Mass: Archie Bleyer Trailblazer Award (National AYA recognition)

Sept 2014              Tampa Bay Business Journal Healthcare Hero: Innovator and Research Category

2014, 2016              Tampa Bay Lightning: Yerrid’s Heros Award

May 2002              Alpha Omega Alpha, Case Western Reserve University

May 2002              CWRU Medical Alumni Association Board of Trustees Award for Outstanding Service and Contributions to the School of Medicine

1998-2002              Dean’s Scholar, Case Western Reserve University

May 1998              Dr. P.K. Bajpai Student Research Award


C.              Contributions to Science

1.              Translational Medicine, Inclusive of Evolutionary Approaches to Cancer: My clinical and research focus has been in sarcomas.  Future investigations will focus on incorporating strategies to predict and leverage cancer responses to therapy into trial designs.  Evolutionary Approaches in Sarcoma Therapy and Trial Design:


a.      Reed DR, Pressley M, Fridley BL, Masanori Hayashi M, Isakoff M, Loeb DM, Makanji R, Metts JL, Roberts RD, Trucco M, Wagner LM, Alexandrow M, Gatenby RA, and Brown JS.  An Evolutionary Framework for Treating Pediatric Sarcomas.  Cancer. 2020 Mar 16.  doi: 10.1002/cncr.32777. [Epub ahead of print] PubMed PMID: 32176331.

b.      Gatenby RA, Artzy-Randrup, Y, Epstein T, Reed DR, and Brown JS.  Eradicating metastatic cancer and the eco-evolutionary dynamics of Anthropocene extinctions.  Cancer Res. 2020 Feb 1;80(3):613-623.  PMID: 31772037

c.      Welch D, Kahen E, Cubitt CL, Brohl AS, Reed DR. Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines. PLoS One. 2019 Sep 24;14(9):e0222228. PMCID: PMC6759167.

d.             Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, Altiok S, Lynch CC, Sullivan DM, Reed DR. Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep. 2015 Nov 25;5:16991. PMCID: PMC4658502.


2.              Early Phase Pediatric Clinical Trials: I am an active clinical trialist with a scope of clinical trials from early phase pediatric trials to collaborative group trials through my Vice Chair role at COGI lead the multi-institutional phase 1/2 network, the Pediatric Cancer Foundation’s Sunshine Project which is centered at Moffitt with patients accruing across the country at over 20 sites.


    1. Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK,  Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized, Double-Blind, Phase II Study of Regorafenib in Patients with Metastatic Osteosarcoma. J. Clin Oncol. 2019 Jun 1;37(16):1424-1431. PMID: 31013172.
    2. Trucco M, Barredo JC, Goldberg J, Leclerc GM, Hale GA, Gill J, Setty B, Smith T, Lush R, Lee JK, Reed DR. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin. Pediatr Blood Cancer. 2018 Sep;65(9):e27224 PMID: 29856514.
    3.                                          Tawbi H, Burgess M, Bolejack V, Van Tine B, Scheutze S, Hu J, D’Angelo S, Attia S,  Reidel R, Priebat D, Movva S, Davis L, Okuno SH, Reed DR, Crowley J, Butterfield L, Lazar A, Rodriguez J, Salazar R, Wistuba I, Baker LH, Maki R, Reinke D, and Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-1501. PMID: 28988646
    4.                                          Reed DR, Mascarenhas L, Manning K, Hale GA, Goldberg J, Gill J, Sandler E,Isakoff MS, Smith T, Caracciolo J, Lush RM, Juan TH, Lee JK, Neuger AM, Sullivan DM. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med. 2016 Feb;5(2):294-303. PMCID: PMC4735769


3.              Adolescent and Young Adult Oncology: As the Director of the Adolescent and Young Adult Program at Moffitt, I am leading research efforts.  For this group of patients we have created interdisciplinary research teams to address biology of AYA cancers in colorectal carcinomas, clinical trial enrollment rates in melanoma during, chemo brain assessments with neurobiology and health outcomes and behavior researchers, and patient education in meningioma.  I am leading the program at our institution and active nationally for this effort.

    1. Jim HSL, Jennewein SL, Quinn GP, Reed DR, Small BJ.  Cognition in Adolescent and Young Adults Diagnosed with Cancer: An Understudied ProblemJ Clin Oncol. 2018 Sep 20;36(27):2752-2754PMCID: PMC7010417
    2.          Sreeraman Kumar R, Thapa R, Kim Y, Khushalani NI, Sondak VK, Reed DR.  Higher than Reported Adolescent and Young Adult Clinical Trial Enrollment During the “Golden Age” of Melanoma Clinical trials.  Cancer Med. 2018 Apr;7(4):991-996.  PMCID: PMC5911596.
    3. Reed DR, Oshrine B, Pratt C, Fridgen O, Elstner C, Wilson L, Soliman H, Lee MC, McLeod HL, Shah B, Donovan KA, Pabbathi S, Turney M, Binitie O, Healy C, Nieder M, Shaw PH, Galligan A, Letson GD, Stern M, Quinn GP, Davies S. Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat. J Adolesc Young Adult Oncol. 2017 Dec;6(4):503-511. PMCID: PMC5725631.
    4. Kothari N, Teer JK, Abbott AM, Srikumar T, Zhang Y, Yoder SJ, Brohl AS, Kim RD, Reed DR, Shibata D. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer. 2016 Sep 15;122(18):2828-35. PMCID: PMC5014625.


4.              Improving Sarcoma Clinical Care: Through novel radiomic analyses, patient/targeted theray matching, development of treatment pathways, and discovery research, I collaborate towards improved sarcoma outcomes.

a.      Jardim-Perassi BV, Mu W, Huang S, Tomaszewski MR, Poleszczuk J, Abdalah MA, Budzevich MM, Dominguez-Viqueira W, Reed DR, Bui MM, Johnson JO, Martinez GV, Gillies RJ.  Targeting hypoxic habitats with hypoxia pro-drug evofosfamide in preclinical models of sarcoma.  bioRxiv 2020.10.06.326934; doi: https://doi.org/10.1101/2020.10.06.326934.  Posted October 7, 2020.

b.      Boddu S, Walko C, Bienasz S, Bui M, Henderson-Jackson E, Naghavi A, Mullinax JE, Joyce DM, Binitie O, Letson GD, Gonzalez RJ, Reed DR, Druta M, Brohl AS.  Clinical utility of genomic profiling in the treatment of advanced sarcomas: a single-center experience. doi: 10.1200/PO.18.00096 JCO Precision Oncology - published online October 19, 2018.

c.      Brohl AS, Kahen E, Yoder S, Teer JK, and DR Reed.  The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation.  Sci Rep. 2017 Nov 8;7(1):14992. PMCID: PMC5678116.

d.      Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, Shinohara ET, Bridge JA, Loeb DM, Borinstein SC, Isakoff MS. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun 15;123(12):2206-2218. PMCID: PMC5485018.

Complete List of Published Work in My Bibliography: